Investing.com - Larimar Therapeutics Inc reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations.
Larimar Therapeutics Inc announced earnings per share of $-0.370 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.587 on revenue of $0.00.
Larimar Therapeutics Inc shares are down 4.96% from the beginning of the year, still down 77.52% from its 52 week high of $13.57 set on November 10, 2021.
Larimar Therapeutics Inc shares gained 3.04% in intra-day trade following the report.
Larimar Therapeutics Inc follows other major Healthcare sector earnings this month
Larimar Therapeutics Inc's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar